Science Corp.
Company · Alameda, California, USA
Neural-engineering company co-founded by Neuralink co-founder Max Hodak, best known for the PRIMA retinal implant for vision loss.
Science acquired the PRIMA system, a wireless photovoltaic chip placed under the retina that is powered by infrared light projected from glasses. It is aimed at people with geographic atrophy, an advanced form of age-related macular degeneration. The company also researches “biohybrid” interfaces that use engineered neurons.
In the news
Science Corp. raises $400 million to take its PRIMA retinal implant to the US
The Series D, reportedly at a $3.5 billion valuation, funds PRIMA's wider European rollout, a planned US launch through the FDA's Humanitarian Device Exemption and Science's biohybrid brain interface program.
PRIMA retinal implant shows vision gains holding at three years
Three-year data from the European PRIMAvera trial, presented at AAO 2026, show a mean gain of about 30 letters, with most serious adverse events in the first six months.
Science Corp. reports its first Stargardt disease patient using the PRIMA retinal implant
A man with the inherited eye disease received the chip in Sydney in May and has begun reading letters and a word in rehabilitation, the company says.
Science Corp. launches PRIMA retinal implant in Europe after CE mark
The wireless retinal chip, approved for vision loss from geographic atrophy, can now be sold across 30 European countries; US approval is still pending.
Science Corp. prepares its first human test of a surface brain sensor for its biohybrid BCI
The pea-sized, 520-electrode sensor will first be tested in stroke patients during surgery; a later version would add lab-grown neurons.
Science Corp. raises $230 million to commercialize its PRIMA retinal implant
The Series C values the company at about $1.5 billion and funds PRIMA's launch plus new clinical programs.
Science Corp. opens its BCI technology stack to other companies, starting with Neurosoft
In a multi-year deal, Swiss start-up Neurosoft will build on Science's clinical-grade neural recording tools, which the companies say cuts the cost of first-in-human trials.
Retinal implant restores reading vision in people with advanced macular degeneration, NEJM study finds
In the PRIMAvera trial, 81% of participants had a meaningful gain in visual acuity at one year with Science Corp.'s PRIMA system.